While Others Are Panicking, Cathie Wood Just Dumped AMD For THESE 3 AI Giants - Should You Too??

The stock market is flashing a chaotic web of mixed signals as we charge toward Q2 earnings, and the tech sector just paid the price. A brutal tech rotation has sent premier AI names plunging, leaving retail investors frozen in uncertainty. But while the masses panic, Wall Street's most polarizing forward thinker is aggressively executing a multi-million dollar playbook. Cathie Wood, the founder of ARK Invest and the mastermind behind the legendary 2020 run that cemented her active management philosophy of disruptive innovation, is reshuffling her portfolio with cold, calculated precision. In a series of decisive moves leading up to mid-July 2026, Wood's flagship funds aggressively paired exposure to former darlings, dumping over $23 million in Advanced Micro Devices AMD, and executing massive liquidations in Roku. Instead of retreating to cash, Wood is rotating capital into high-conviction frontiers. Demonstrating her signature courage to buy the dip, ARK has snapped up massive blocks of shares in two dominant artificial intelligence giants and one breakthrough AI-powered healthcare innovator. This isn't just a rebalancing act. It's a direct window into where the next wave of exponential wealth is being generated. Wood's willingness to absorb short-term volatility to capture massive long-term secular trends is the cornerstone of her investing DNA. In this video, we are breaking down the exact numbers behind ARK's latest transactions and setting the stage to analyze the three specific high-upside stocks aligning with her bold, newly reshuffled vision. If you want to invest like the smart money, you cannot afford to miss this. Let's dive in. Let's begin with the crown jewel of our discussion, Space Exploration Technologies Corp, trading under the ticker SPC-X, which recently saw Wood's largest transaction to date after deploying over $52 million to snap up 349,000 shares across her funds. While the broader public still views this giant primarily as a rocket and satellite business, the smartest minds on Wall Street are realizing that SpaceX has aggressively transformed into a powerhouse in the AI infrastructure domain. Following its monumental initial public offering, a classic post-IPO cooling period has pulled the stock down to around $152 per share, dropping roughly 32.6% from its mid-June high watermark of $225.6. This price correction has nothing to do with deteriorating fundamentals. Rather, it is a healthy reset of speculative retail fervor colliding with broader market anxieties over macroeconomics and temporary float unlocked dynamics. The structural beauty of SpaceX lies in its multi-layered, vertically integrated business model. Starlink's dominant cash-generating satellite internet engine provides the capital foundation, while the launch division maintains a near monopoly on orbital logistics. But the real explosive catalyst is the company's sudden ascension into the role of the ultimate AI landlord. By absorbing Elon Musk's xAI venture earlier this year and sealing a jaw-dropping all-stock $60 billion acquisition of Cursor, the premier AI coding assistant boasting over $4 billion in annualized revenue, SpaceX has bypassed the long development cycle to capture a major enterprise AI footprint. This massive infrastructure shift is already yielding fruit with the joint launch of the Grok 4.5 frontier model, which delivers unparalleled token efficiency and cuts developer output costs by more than four times compared to chief rivals. As global enterprises demand massive reductions in token expenses, SpaceX's immense compute scale, anchored by the colossal million H100 equivalent Colossus supercomputer cluster, places it in a tier of its own. Furthermore, its future roadmap features the mind-bending potential of space-based orbital data centers. This radical approach could completely bypass terrestrial power and cooling constraints, fundamentally altering the economics of global artificial intelligence. While current financials still show temporary capital intensive losses, conservative estimates project revenue soaring from an expected $39 billion in 2026 to an astounding $365 billion by 2030, with AI scaling to comprise over 90% of the entire business. Trading at a deeply discounted 13.4 times its projected 2030 earnings compared to the broader tech sector's 25 times median, SpaceX represents a highly compelling long-term secular growth story for forward-looking investors ready to capitalize on an generational market pullback. Transitioning from the heights of orbit back to the cutting edge of biological computation, our second stock is the pharmaceutical titan Eli Lilly, trading under the ticker LLY, which captured a massive $25.8 million investment from ARK Invest. While the mainstream media remains obsessed with the blockbuster success of the company's weight loss drugs Mounjaro and Zepbound, sophisticated investors are looking at a much larger second-order effect. Lilly is taking the historic cash flows generated by its dominant obesity franchise and aggressively funneling them into building an AI native drug discovery and manufacturing platform. The business has effectively entered a self-reinforcing flywheel, growing like a hypergrowth tech firm while maintaining an 80% gross margin structure. Let's look at the hard data. In fiscal year 2025, Eli Lilly's revenue surged 45% year-over-year to $65 billion. That momentum accelerated violently into Q1 2026, with revenue climbing 56% to $19.8 billion, while GAAP earnings per share skyrocketed 170%. Management consequently raised full-year 2026 revenue guidance to a staggering 82 to 85 billion dollars. Looking ahead, 2027 revenue is poised to approach $100 billion with free cash flow reaching 30 billion. Instead of resting, Lilly is spending billions on research and development and capital expenditures to build the most powerful AI supercomputer in the pharmaceutical industry in collaboration with Nvidia. This massive compute capacity, combined with their Tune Lab platform housing over $1 billion in proprietary clinical data sets, allows Lilly to operate like a scaled biomedical search engine. By using artificial intelligence to optimize drug design and deploy robotic digital twins across their manufacturing facilities, they are dramatically scaling throughput. Even a minor 1% improvement in supply throughput on a $100 billion revenue base unlocks an extra billion dollars in revenue, translating to $800 million in gross profit. If Lilly leverages AI to drive 500 basis points of margin expansion, revenue could compound to $170 billion by 2030, with free cash flow hitting 60 billion. By using its obesity empire to bankroll an artificial intelligence revolution, >> [music] >> Eli Lilly is quietly transforming into the ultimate biomedical compounder. Now shifting our focus to a tech giant that is rapidly weaponizing consumer scale to build an unbeatable infrastructure fortress, our third stock is Meta Platforms, trading under the ticker MT which recently received a significant $20.7 million position boost from Cathie Wood's ETFs. Wall Street initially panicked earlier this year when Meta raised its massive full-year capital expenditure guidance to a range of $125 billion to $145 billion. But at just under 20 times forward earnings, Meta is easily the cheapest of the big four hyperscalers with a valuation compressing to an incredibly cheap 16 times by fiscal year 2028. The market is finally realizing that this staggering capital expenditure is not dead money. It is a massive rentable asset. The highly anticipated launch of Meta Cloud marks a monumental shift allowing Meta to sell raw compute and host models for third-party enterprises. Analysts suggest that renting out just a single gigawatt of capacity could generate upwards of $20 billion in revenue, which at an estimated 85% operating margin translates to a massive $17 billion in operating income. Moreover, Meta is executing a ruthless pricing strategy to capture enterprise market share. Along with its new creative Muse image model, the company recently rolled out its advanced agentic Muse Spark 1.1 model offering a pay-as-you-go public API at $1.25 per million input tokens. This is roughly 25% of what premium rivals like OpenAI and Anthropic charge representing a direct assault on the business-to-business AI landscape. Even if Meta chooses to host competing models or partner with frontier labs, it It an unbeatable trump card, a distribution ecosystem of 3.56 billion daily active users. This immense scale, paired with a massive 52% operating margin in its core family of apps, ensures that Meta will monetize artificial intelligence faster than almost anyone else. By positioning itself as both an AI software distributor and an infrastructure landlord, Meta is primed for a massive re-rating. Wood's latest moves highlight a shift away from legacy hardware and toward high-margin AI platforms. Keep these three plays on your radar. Make sure to hit that subscribe button, smash the like, and comment below with your favorite stock. Until next time, stay sharp and trade smart.